Citadel Advisors
GBT

Citadel Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Citadel Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-51,397
Closed -$3.5M – 16074
2022
Q3 		$3.5M Sell
51,397
-1,300,157
-96% -$71.7M ﹤0.01% 4499
2022
Q2 		$43.2M Sell
1,351,554
-614,378
-31% -$18M 0.01% 1137
2022
Q1 		$68.1M Buy
1,965,932
+280,076
+17% +$8.37M 0.01% 883
2021
Q4 		$49.3M Buy
1,685,856
+1,650,927
+4,727% +$51.1M 0.01% 1176
2021
Q3 		$890K Buy
+34,929
New +$1.03M ﹤0.01% 8447
2021
Q2 		– Sell
-1,097,553
Closed -$42.9M – 14770
2021
Q1 		$44.7M Buy
1,097,553
+720,308
+191% +$33.1M 0.01% 1133
2020
Q4 		$16.3M Sell
377,245
-298,927
-44% -$14.7M ﹤0.01% 2029
2020
Q3 		$37.3M Buy
676,172
+385,407
+133% +$24.5M 0.01% 1055
2020
Q2 		$18.4M Buy
290,765
+102,171
+54% +$7.01M 0.01% 1578
2020
Q1 		$9.64M Buy
188,594
+1,244
+0.7% +$83.3K ﹤0.01% 1895
2019
Q4 		$14.9M Buy
187,350
+174,441
+1,351% +$10.3M 0.01% 1774
2019
Q3 		$626K Sell
12,909
-214,698
-94% -$11.2M ﹤0.01% 6374
2019
Q2 		$12M Buy
227,607
+29,402
+15% +$1.69M 0.01% 1964
2019
Q1 		$10.5M Buy
198,205
+166,583
+527% +$8.19M 0.01% 2008
2018
Q4 		$1.3M Sell
31,622
-38,729
-55% -$1.45M ﹤0.01% 4890
2018
Q3 		$2.67M Buy
70,351
+39,619
+129% +$1.75M ﹤0.01% 3912
2018
Q2 		$1.39M Sell
30,732
-19,178
-38% -$873K ﹤0.01% 4671
2018
Q1 		$2.41M Sell
49,910
-666,701
-93% -$37.2M ﹤0.01% 3451
2017
Q4 		$28.2M Buy
716,611
+449,828
+169% +$16.8M 0.02% 959
2017
Q3 		$8.28M Sell
266,783
-1,178,352
-82% -$33.1M 0.01% 1779
2017
Q2 		$39.5M Buy
1,445,135
+607,883
+73% +$18.1M 0.03% 610
2017
Q1 		$30.9M Buy
837,252
+807,316
+2,697% +$20.3M 0.03% 693
2016
Q4 		$433K Buy
29,936
+1,809
+6% +$31.8K ﹤0.01% 5133
2016
Q3 		$648K Buy
+28,127
New +$536K ﹤0.01% 4454

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's GBT Position: Q4 2022 in Review

Citadel Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 51,397 shares — an estimated $3.5M sold.

Citadel Advisors first reported a position in GBT in Q3 2016 and held it in 24 quarters. The position peaked at $68.1M in Q1 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Citadel Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 51,397 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $3.5M.
  • Citadel Advisors first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 24 quarters.
  • Citadel Advisors's Global Blood Therapeutics, Inc. position peaked at $68.1M in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.